CUMS Mouse Model: Gold Standard for Antidepressant Efficacy Assessment

Ace Therapeutics is proud to present our validated CUMS mouse model, a powerful tool designed to accelerate your antidepressant drug development by accurately simulating human-relevant depressive phenotypes in mice. This exclusive case study offers unparalleled insights into the intricacies of depression research, making it an invaluable resource for pharmaceutical professionals.

Key Value Snapshot

High-Fidelity Clinical Simulation

Utilizes 3-8 weeks of randomized mild stressors (e.g., circadian disruption, damp bedding) to replicate human chronic stress-induced neuroendocrine dysregulation (elevated corticosterone) and behavioral despair (increased immobility in FST/TST). Accurately recapitulates depressive-like phenotypes, establishing a cornerstone of clinical predictability for drug screening.

Standardized Protocol & Metrics

Employs BALB/c male mice (5-7 weeks old) in a validated 35-day modeling protocol. Core behavioral endpoints include sucrose preference test (SPT), spontaneous alternation in Y-maze (SA), and forced swim test (FST) immobility time. Provides multi-dimensional validation of antidepressant potential-from neurobehavioral to physiological/biochemical levels..

Efficacy Validation

Demonstrated through positive control (fluoxetine) and test compounds. Significant amelioration of depressive-like behaviors observed in medium/high-dose groups after 28-day administration, evidenced by restored sucrose preference and reduced behavioral despair. Delivers a comprehensive "model-to-efficacy" evidence chain for drug development.

Download Now to Access

• Full stressor implementation timeline
• Behavioral testing SOPs with QC thresholds
• Statistical analysis criteria for efficacy claims
• Technical consultation contact

Elevate your antidepressant drug pipeline with CUMS mouse models widely cited in peer-reviewed studies.

You might be interested in...